Eisai Partnership a Ringing Endorsement of EZH2
Epizyme Inc. views its potential $206 million new partnership agreement with Eisai Co. Ltd. as an endorsement of its research and development efforts in EZH2, and as a complement to its recent deal with GlaxoSmithKline plc within its overall business strategy.
BioWorld Today Contributing Writer
Epizyme Inc. views its potential $206 million new partnership agreement with Eisai Co. Ltd.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter